Corvus Pharmaceuticals Inc (CRVS)

02:36 AM

FY2024 EPS Estimates for CRVS Decreased by Cantor Fitzgerald - MarketBeat

02:36 AM

Nov 16, 2024

Corvus Pharmaceuticals (NASDAQ:CRVS) Sees Large Volume IncreaseWhat's Next? - MarketBeat

Nov 16, 2024

Nov 14, 2024

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2024 Earnings Call Transcript - MSN

Nov 14, 2024

Nov 14, 2024

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares Sold by Towerview LLC - MarketBeat

Nov 14, 2024

Nov 14, 2024

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis - The Manila Times

Nov 14, 2024

Nov 14, 2024

Corvus drug shows promise in systemic sclerosis models - Investing.com

Nov 14, 2024

Nov 14, 2024

Corvus' Soquelitinib Shows Promise in Preventing Systemic Sclerosis Lung Damage in Key Study | CRVS Stock News - StockTitan

Nov 14, 2024

Nov 13, 2024

Corvus Pharmaceuticals target raised to $13 by Jefferies - Investing.com UK

Nov 13, 2024

Nov 13, 2024

Corvus Pharmaceuticals: The Market Likes The Story (NASDAQ:CRVS) - Seeking Alpha

Nov 13, 2024

Nov 13, 2024

Corvus Pharmaceuticals (NASDAQ:CRVS) Given New $14.00 Price Target at Oppenheimer - MarketBeat

Nov 13, 2024

Nov 13, 2024

Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up Following Analyst Upgrade - MarketBeat

Nov 13, 2024

Nov 13, 2024

Corvus Pharmaceuticals Inc (CRVS) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid ... By GuruFocus - Investing.com Canada

Nov 13, 2024

Nov 13, 2024

Corvus Pharmaceuticals Reports Q3 2024 Financial Results - TipRanks

Nov 13, 2024

Nov 12, 2024

Corvus: Q3 Earnings Snapshot - San Antonio Express-News

Nov 12, 2024

Nov 12, 2024

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results - The Manila Times

Nov 12, 2024

Nov 12, 2024

Corvus Pharma Reports $41.7M Cash Position, Advances Key Clinical Trials Despite Q3 Loss | CRVS Stock News - StockTitan

Nov 12, 2024

Nov 11, 2024

Corvus Pharmaceuticals (NASDAQ:CRVS) Reaches New 12-Month HighWhat's Next? - MarketBeat

Nov 11, 2024

Nov 09, 2024

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer - The Manila Times

Nov 09, 2024

Nov 09, 2024

Corvus' Ciforadenant Shows Promise in Prostate Cancer Treatment, Doubles Response Rate | CRVS Stock News - StockTitan

Nov 09, 2024

Nov 08, 2024

Palantir Technologies Inc Cl A (PLTR-N) QuotePress Release - The Globe and Mail

Nov 08, 2024

Nov 06, 2024

Corvus Pharmaceuticals (CRVS) Scheduled to Post Earnings on Tuesday - MarketBeat

Nov 06, 2024

Nov 06, 2024

Corvus Pharmaceuticals stock soars to 52-week high of $9.69 - Investing.com

Nov 06, 2024

Nov 06, 2024

Sunrun Inc (RUN-Q) QuotePress Release - The Globe and Mail

Nov 06, 2024

Nov 06, 2024

Microsoft Corp (MSFT-Q) QuotePress Release - The Globe and Mail

Nov 06, 2024

Nov 06, 2024

T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - GlobeNewswire Inc.

Nov 06, 2024

Nov 06, 2024

Godaddy Inc (GDDY-N) QuotePress Release - The Globe and Mail

Nov 06, 2024

Nov 05, 2024

Enersys Inc (ENS-N) QuotePress Release - The Globe and Mail

Nov 05, 2024

Nov 05, 2024

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024 - WICZ

Nov 05, 2024

Nov 05, 2024

Corvus Pharmaceuticals (NASDAQ:CRVS) Reaches New 1-Year HighStill a Buy? - MarketBeat

Nov 05, 2024

Nov 05, 2024

Amer Superconductor (AMSC-Q) QuotePress Release - The Globe and Mail

Nov 05, 2024

Nov 05, 2024

TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail

Nov 05, 2024

Nov 04, 2024

Toll Brothers Inc (TOL-N) QuotePress Release - The Globe and Mail

Nov 04, 2024

Nov 04, 2024

Corvus Pharmaceuticals (NASDAQ:CRVS) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat

Nov 04, 2024

Nov 03, 2024

United Parcel Service (UPS-N) QuotePress Release - The Globe and Mail

Nov 03, 2024

Nov 03, 2024

S&P GSCI (GDF25) Quote - The Globe and Mail

Nov 03, 2024

Nov 01, 2024

Lumber Physical (LBU23) Quote - The Globe and Mail

Nov 01, 2024

Oct 31, 2024

Corvus Pharmaceuticals (NASDAQ:CRVS) Lowered to "Sell" Rating by StockNews.com - MarketBeat

Oct 31, 2024

Oct 30, 2024

Corvus Pharmaceuticals stock soars to 52-week high of $8.74 By Investing.com - Investing.com Canada

Oct 30, 2024

Oct 29, 2024

Corvus Pharmaceuticals stock soars to 52-week high of $8.74 - Investing.com

Oct 29, 2024

Oct 28, 2024

Corvus Pharmaceuticals (NASDAQ:CRVS) Hits New 12-Month HighHere's What Happened - MarketBeat

Oct 28, 2024

Oct 28, 2024

Where are the Opportunities in (CRVS) - Stock Traders Daily

Oct 28, 2024

Oct 27, 2024

Msc Industrial Direct Company (MSM-N) QuotePress Release - The Globe and Mail

Oct 27, 2024

Oct 26, 2024

Insiders Rewarded With US$3.9m Addition To Investment As Corvus Pharmaceuticals Stock Hits US$480m - Simply Wall St

Oct 26, 2024

Oct 25, 2024

Corvus Pharmaceuticals (NASDAQ:CRVS) Trading Up 6%Here's Why - MarketBeat

Oct 25, 2024

Oct 24, 2024

Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Rating Upgraded by Mizuho - MarketBeat

Oct 24, 2024

Oct 23, 2024

Corvus Pharmaceuticals (NASDAQ:CRVS) Lifted to "Hold" at StockNews.com - MarketBeat

Oct 23, 2024

Oct 23, 2024

Corvus Pharmaceuticals secures new South San Francisco lease - Investing.com

Oct 23, 2024

Oct 23, 2024

Corvus Pharmaceuticals secures new South San Francisco lease By Investing.com - Investing.com UK

Oct 23, 2024

Oct 22, 2024

Corvus Pharmaceuticals (NASDAQ:CRVS) Sets New 52-Week HighShould You Buy? - MarketBeat

Oct 22, 2024

Oct 21, 2024

Corvus Pharmaceuticals stock soars to 52-week high of $7.67 By Investing.com - Investing.com Australia

Oct 21, 2024

Oct 21, 2024

Corvus Pharmaceuticals stock soars to 52-week high of $7.67 - Investing.com India

Oct 21, 2024

Oct 19, 2024

CRVS Hits 52-week High Ahead Of Atopic Dermatitis Trial Results - RTTNews

Oct 19, 2024

Oct 17, 2024

Insiders of Corvus Pharmaceuticals Getting Good Value On Their US$1.03m Investment - Yahoo Finance

Oct 17, 2024

Oct 16, 2024

Upward Trajectory: Corvus Pharmaceuticals Inc (CRVS) Posts a Slidee, Closing at 6.72 - The Dwinnex

Oct 16, 2024